A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs AMG 529 (Primary) ; AMG 529 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 10 Nov 2017 Planned End Date changed from 6 Nov 2017 to 13 Nov 2017.
- 10 Nov 2017 Planned primary completion date changed from 6 Nov 2017 to 13 Nov 2017.